Aktieanalys

Magle Chemoswed Q3: Initial take - Redeye

Redeye Publicerad: 24 Oct 12:03

Redeye leaves an initial comment following the Q3 report published by Magle this morning. During the third quarter of 2024, Magle completed the merger with pK Biotech (pK Chemicals) and is closing the merger with Amniotics. As previously explained, we are encouraged by the company’s M&A activity and believe that both of these are poised to generate long-term shareholder value for Magle. This is evident in the financials of the company’s Q3 report, as the company reported significantly higher sales figures and EBIT than previous quarters.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045796/magle-chemoswed-q3-initial-take-2?utm_source=finwire&utm_medium=RSS

Nyheter om Magle Chemoswed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!